WO2009012082A1 - Methods for treating anxiety - Google Patents
Methods for treating anxiety Download PDFInfo
- Publication number
- WO2009012082A1 WO2009012082A1 PCT/US2008/069428 US2008069428W WO2009012082A1 WO 2009012082 A1 WO2009012082 A1 WO 2009012082A1 US 2008069428 W US2008069428 W US 2008069428W WO 2009012082 A1 WO2009012082 A1 WO 2009012082A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- anxiety
- atoms
- disorder
- alkyl
- compound
- Prior art date
Links
- GRZMKKUGHIECFK-MNOVXSKESA-N N[C@H]([C@H](c1ccncc1)O)C(N1CCCC1)=O Chemical compound N[C@H]([C@H](c1ccncc1)O)C(N1CCCC1)=O GRZMKKUGHIECFK-MNOVXSKESA-N 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/4025—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil not condensed and containing further heterocyclic rings, e.g. cromakalim
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
- A61K31/4535—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a heterocyclic ring having sulfur as a ring hetero atom, e.g. pizotifen
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
- A61K31/4545—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/4709—Non-condensed quinolines and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/18—Drugs for disorders of the endocrine system of the parathyroid hormones
- A61P5/22—Drugs for disorders of the endocrine system of the parathyroid hormones for decreasing, blocking or antagonising the activity of calcitonin
Abstract
Description
Claims
Priority Applications (10)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP08781509.8A EP2175850B1 (en) | 2007-07-17 | 2008-07-08 | Treatment of anxiety |
CN2008801024044A CN101778628B (en) | 2007-07-17 | 2008-07-08 | Methods for treating anxiety |
BRPI0813832-0A2A BRPI0813832A2 (en) | 2007-07-17 | 2008-07-08 | ANXIETY TREATMENT METHODS |
ES08781509.8T ES2621160T3 (en) | 2007-07-17 | 2008-07-08 | Anxiety treatment |
CA2693369A CA2693369A1 (en) | 2007-07-17 | 2008-07-08 | Methods for treating anxiety |
US12/669,304 US8211917B2 (en) | 2007-07-17 | 2008-07-08 | Methods for treating anxiety |
JP2010517073A JP2010533720A (en) | 2007-07-17 | 2008-07-08 | Methods for treating anxiety |
NZ582874A NZ582874A (en) | 2007-07-17 | 2008-07-08 | Methods for treating anxiety |
AU2008276278A AU2008276278A1 (en) | 2007-07-17 | 2008-07-08 | Methods for treating anxiety |
RU2010105135/15A RU2491931C2 (en) | 2007-07-17 | 2008-07-08 | Methods of treating anxiety |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US95014407P | 2007-07-17 | 2007-07-17 | |
US60/950,144 | 2007-07-17 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2009012082A1 true WO2009012082A1 (en) | 2009-01-22 |
Family
ID=39810180
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/US2008/069428 WO2009012082A1 (en) | 2007-07-17 | 2008-07-08 | Methods for treating anxiety |
Country Status (12)
Country | Link |
---|---|
US (1) | US8211917B2 (en) |
EP (1) | EP2175850B1 (en) |
JP (1) | JP2010533720A (en) |
KR (1) | KR20100047261A (en) |
CN (1) | CN101778628B (en) |
AU (1) | AU2008276278A1 (en) |
BR (1) | BRPI0813832A2 (en) |
CA (1) | CA2693369A1 (en) |
ES (1) | ES2621160T3 (en) |
NZ (1) | NZ582874A (en) |
RU (1) | RU2491931C2 (en) |
WO (1) | WO2009012082A1 (en) |
Cited By (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2011009061A1 (en) * | 2009-07-17 | 2011-01-20 | Allergan, Inc. | Compositions comprising a cholinesterase inhibitor for treating cognitive disorders |
WO2011034912A1 (en) * | 2009-09-16 | 2011-03-24 | Allergan, Inc. | Compositions and methods for treating spasticity |
WO2011034915A1 (en) * | 2009-09-16 | 2011-03-24 | Allergan, Inc. | Compositions and methods for treating disorders of gastrointestinal motility |
WO2011034920A1 (en) * | 2009-09-16 | 2011-03-24 | Allergan, Inc. | Compositions and methods for treating seizure disorders |
Families Citing this family (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CA2595522C (en) * | 2005-01-26 | 2013-09-10 | Allergan, Inc. | 3-aryl-3-hydroxy-2-amino-propionic acid amides, 3-heteroaryl-3-hydroxy-2-amino-propionic acid amides and related compounds having analgesic and/or immuno stimulant activity |
ES2659271T3 (en) * | 2012-10-15 | 2018-03-14 | Orion Corporation | Veterinary method to relieve noise aversion |
Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2003045928A1 (en) * | 2001-11-26 | 2003-06-05 | Genzyme Corporation | Diastereoselective synthesis of udp-glucose : n-acylsphingosine glucosyltransferase inhibitors |
WO2006081252A2 (en) * | 2005-01-26 | 2006-08-03 | Allergan, Inc. | Use of 1-benzyl-1-hydr0xy-2, 3-diamino-propyl amines, 3-benzyl-3-hydroxy-2-amino-propionic acid amides and related compounds as analgesics |
WO2008109610A1 (en) * | 2007-03-06 | 2008-09-12 | Allergan, Inc. | Methods for treating cognitive disorders using 3-aryl-3-hydroxy-2-amino-propionic acid amides, 3-heteroaryl-3-hydroxy-2-amino-propionic acid amides and related compounds |
WO2008109287A1 (en) * | 2007-03-06 | 2008-09-12 | Allergan, Inc. | Methods for treating cognitive disorders using 1-benzyl-1-hydroxy-2,3-diamino-propyl amines, 3-benzyl-3-hydroxy-2-amino-propionic acid amides and related compounds |
Family Cites Families (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6071970A (en) * | 1993-02-08 | 2000-06-06 | Nps Pharmaceuticals, Inc. | Compounds active at a novel site on receptor-operated calcium channels useful for treatment of neurological disorders and diseases |
HUP0004557A3 (en) * | 1997-12-04 | 2002-03-28 | Allergan Inc Irvine | Substituted imidazole derivatives having agonist-like activity at alpha 2b or 2b/2c adrenergic receptors and pharmaceuticals containing the same |
BRPI0412263B1 (en) * | 2003-07-22 | 2019-10-15 | Arena Pharmaceuticals, Inc. | Diaryl and aryl heteroaryl urea derivatives, use and pharmaceutical composition containing them, as well as process for preparing said composition |
ATE356129T1 (en) * | 2004-01-06 | 2007-03-15 | Taisho Pharmaceutical Co Ltd | TRIAZACYCLOPENTA(CD)INDENDERIVATES |
WO2008109286A1 (en) * | 2007-03-06 | 2008-09-12 | Allergan, Inc. | Methods for treating cognitive disorders using 1-aryl-1-hydroxy-2,3-diamino-propyl amines, 1-heteroaryl-1-hydroxy-2,3-diamino-propyl amines and related compounds |
US8173683B2 (en) * | 2007-03-06 | 2012-05-08 | Allergan, Inc. | Methods for treating cognitive disorders |
-
2008
- 2008-07-08 AU AU2008276278A patent/AU2008276278A1/en not_active Abandoned
- 2008-07-08 US US12/669,304 patent/US8211917B2/en active Active
- 2008-07-08 ES ES08781509.8T patent/ES2621160T3/en active Active
- 2008-07-08 KR KR1020107003376A patent/KR20100047261A/en not_active Application Discontinuation
- 2008-07-08 JP JP2010517073A patent/JP2010533720A/en active Pending
- 2008-07-08 WO PCT/US2008/069428 patent/WO2009012082A1/en active Application Filing
- 2008-07-08 CA CA2693369A patent/CA2693369A1/en not_active Abandoned
- 2008-07-08 EP EP08781509.8A patent/EP2175850B1/en active Active
- 2008-07-08 BR BRPI0813832-0A2A patent/BRPI0813832A2/en not_active IP Right Cessation
- 2008-07-08 RU RU2010105135/15A patent/RU2491931C2/en not_active IP Right Cessation
- 2008-07-08 CN CN2008801024044A patent/CN101778628B/en not_active Expired - Fee Related
- 2008-07-08 NZ NZ582874A patent/NZ582874A/en not_active IP Right Cessation
Patent Citations (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2003045928A1 (en) * | 2001-11-26 | 2003-06-05 | Genzyme Corporation | Diastereoselective synthesis of udp-glucose : n-acylsphingosine glucosyltransferase inhibitors |
WO2006081252A2 (en) * | 2005-01-26 | 2006-08-03 | Allergan, Inc. | Use of 1-benzyl-1-hydr0xy-2, 3-diamino-propyl amines, 3-benzyl-3-hydroxy-2-amino-propionic acid amides and related compounds as analgesics |
WO2006081273A1 (en) * | 2005-01-26 | 2006-08-03 | Allergan, Inc. | 3-aryl-3-hydroxy-2-amino-propionic acid amides, 3-heteroayryl-3-hydroxy-2-amino-propionic acid amides and related compounds having analgesic and/or immunostimulant activity |
WO2008109610A1 (en) * | 2007-03-06 | 2008-09-12 | Allergan, Inc. | Methods for treating cognitive disorders using 3-aryl-3-hydroxy-2-amino-propionic acid amides, 3-heteroaryl-3-hydroxy-2-amino-propionic acid amides and related compounds |
WO2008109287A1 (en) * | 2007-03-06 | 2008-09-12 | Allergan, Inc. | Methods for treating cognitive disorders using 1-benzyl-1-hydroxy-2,3-diamino-propyl amines, 3-benzyl-3-hydroxy-2-amino-propionic acid amides and related compounds |
Non-Patent Citations (2)
Title |
---|
JUDE U OHAERI: "The Management of Anxiety and Depressive Disorders: A Review", INTERNATIONAL JOURNAL OF MENTAL HEALTH AND ADDICTION, SPRINGER-VERLAG, NE, vol. 4, no. 2, 27 April 2006 (2006-04-27), pages 103 - 118, XP019413320, ISSN: 1557-1882 * |
WALF A A ET AL: "The use of the elevated plus maze as an assay of anxiety-related behavior in rodents", NATURE PROTOCOLS 200703 GB, vol. 2, no. 2, March 2007 (2007-03-01), pages 322 - 328, XP002499409, ISSN: 1754-2189 1750-2799 * |
Cited By (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2011009061A1 (en) * | 2009-07-17 | 2011-01-20 | Allergan, Inc. | Compositions comprising a cholinesterase inhibitor for treating cognitive disorders |
CN102497861A (en) * | 2009-07-17 | 2012-06-13 | 阿勒根公司 | Compositions comprising a cholinesterase inhibitor for treating cognitive disorders |
US9492543B2 (en) | 2009-07-17 | 2016-11-15 | Allergan, Inc. | Compositions for treating cognitive disorders |
WO2011034912A1 (en) * | 2009-09-16 | 2011-03-24 | Allergan, Inc. | Compositions and methods for treating spasticity |
WO2011034915A1 (en) * | 2009-09-16 | 2011-03-24 | Allergan, Inc. | Compositions and methods for treating disorders of gastrointestinal motility |
WO2011034920A1 (en) * | 2009-09-16 | 2011-03-24 | Allergan, Inc. | Compositions and methods for treating seizure disorders |
US8217059B2 (en) | 2009-09-16 | 2012-07-10 | Allergan, Inc. | Compositions and methods for treating spasticity |
US8242141B2 (en) | 2009-09-16 | 2012-08-14 | Allergan, Inc. | Compositions and methods for treating seizure disorders |
US8404721B2 (en) | 2009-09-16 | 2013-03-26 | Allergan, Inc. | Compositions and methods for treating seizure disorders |
Also Published As
Publication number | Publication date |
---|---|
RU2010105135A (en) | 2011-08-27 |
ES2621160T3 (en) | 2017-07-03 |
KR20100047261A (en) | 2010-05-07 |
US20100197730A1 (en) | 2010-08-05 |
NZ582874A (en) | 2012-06-29 |
CN101778628B (en) | 2013-02-06 |
BRPI0813832A2 (en) | 2015-01-06 |
AU2008276278A1 (en) | 2009-01-22 |
JP2010533720A (en) | 2010-10-28 |
RU2491931C2 (en) | 2013-09-10 |
CN101778628A (en) | 2010-07-14 |
CA2693369A1 (en) | 2009-01-22 |
EP2175850A1 (en) | 2010-04-21 |
US8211917B2 (en) | 2012-07-03 |
EP2175850B1 (en) | 2017-01-11 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
EP2175850B1 (en) | Treatment of anxiety | |
JP2023022227A (en) | Method of treating liver fibrosis | |
JP5450434B2 (en) | How to treat arthritis | |
JP2003525903A (en) | New uses of cholinesterase inhibitors | |
CN105120866A (en) | Toxic aldehyde related diseases and treatment | |
JP2007519649A5 (en) | ||
JP2005509642A5 (en) | ||
RU2007101653A (en) | Derivatives of 1-azabicyclo [3.3.1] NONANOV | |
JP2010520154A (en) | AMPA receptor antagonists and NMDA receptor antagonists for neurodegenerative diseases | |
CA2597327A1 (en) | Antibiotic macrolides | |
JP2003505378A5 (en) | ||
EP2477624B1 (en) | Compounds for use in the treatment of seizure disorders | |
CA2474246A1 (en) | Alkylammonium salts of omeprazole and esomeprazole | |
WO2020221274A1 (en) | Method for treating cough by using diaminopyrimidine compound | |
JP4598674B2 (en) | Schizophrenia treatment | |
WO2000016774A1 (en) | Method for solubilizing pyridonecarboxylic acid, solubilizer therefor, aqueous solution preparations containing pyridonecarboxylic acid and process for producing the same | |
US20110212995A1 (en) | Compositions and methods for treating spasticity | |
WO2021207486A1 (en) | Treatments | |
WO1994002124A1 (en) | Anti-hiv agent | |
WO2011034915A1 (en) | Compositions and methods for treating disorders of gastrointestinal motility |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
WWE | Wipo information: entry into national phase |
Ref document number: 200880102404.4 Country of ref document: CN |
|
121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 08781509 Country of ref document: EP Kind code of ref document: A1 |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2693369 Country of ref document: CA Ref document number: 12669304 Country of ref document: US Ref document number: 2008276278 Country of ref document: AU Ref document number: MX/A/2010/000627 Country of ref document: MX |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2010517073 Country of ref document: JP |
|
NENP | Non-entry into the national phase |
Ref country code: DE |
|
WWE | Wipo information: entry into national phase |
Ref document number: 582874 Country of ref document: NZ |
|
REEP | Request for entry into the european phase |
Ref document number: 2008781509 Country of ref document: EP |
|
WWE | Wipo information: entry into national phase |
Ref document number: 739/DELNP/2010 Country of ref document: IN Ref document number: 2008781509 Country of ref document: EP |
|
ENP | Entry into the national phase |
Ref document number: 2008276278 Country of ref document: AU Date of ref document: 20080708 Kind code of ref document: A |
|
ENP | Entry into the national phase |
Ref document number: 20107003376 Country of ref document: KR Kind code of ref document: A |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2010105135 Country of ref document: RU |
|
ENP | Entry into the national phase |
Ref document number: PI0813832 Country of ref document: BR Kind code of ref document: A2 Effective date: 20100118 |